Clinical Development Disease Pharma Companies 
Drug Target Review
SEPTEMBER 5, 2024
However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.
The Connected Lab
APRIL 8, 2020
The cost to develop a new prescription medicine that gains market approval has gone up 145% to $2.6 billion and takes an average of 10 years to develop 1. To this day, more than 400 million people suffer from rare diseases and 95% of rare diseases lack an FDA approved treatment 3. Policy & Medicine , 21 Mar.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
H1 Blog
JUNE 7, 2023
Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. In a recent article in Clinical Leader , Randy Krauss, head and executive director of metrics, analytics, and performance, Merck & Co., There is a tendency to want to measure everything.” The Michael J.
The Pharma Data
SEPTEMBER 11, 2020
While stories from news outlets indicate the peak of the infection has passed in most European countries, cases of the disease continue to rise in other parts of the world, especially Latin America and Africa. This week’s round up dives into developments from companies based in Australia and the US. “The
Drug Target Review
OCTOBER 1, 2024
Looking ahead, what exciting developments or advancements do you foresee in your field of STEM, and how do you envision your own research contributing to those future innovations?
Vial
MARCH 1, 2024
Recent and significant activities among these top CROs based in the US include the acquisition of Pharmaceutical Product Development (PPD), a global industry leader in clinical development and analytical services, by Thermo Fisher Scientific Inc. completed its acquisition of PPD.
The Premier Consulting Blog
OCTOBER 21, 2024
The FDA defines a serious condition as “a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.” This pathway has been used since 1992, benefiting both sponsors and patients in various disease areas including oncology, neurology, infectious disease, and rare disease.
Expert insights. Personalized for you.
111 
Let's personalize your content